Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $11.17.
Several research analysts have issued reports on CMPX shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group lifted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th.
Read Our Latest Stock Report on CMPX
Institutional Investors Weigh In On Compass Therapeutics
Compass Therapeutics Stock Down 8.0 %
Shares of NASDAQ CMPX opened at $3.45 on Tuesday. The stock has a market cap of $474.68 million, a PE ratio of -9.32 and a beta of 1.17. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The business has a 50-day moving average price of $2.24 and a 200 day moving average price of $1.78.
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Sell-side analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current year.
About Compass Therapeutics
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Recommended Stories
- Five stocks we like better than Compass Therapeutics
- How to Read Stock Charts for Beginners
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.